- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06184633
HOLLANDSK vægtkontrol i atrieflimren undersøgelse (DUTCH-WAIST)
HOLLANDSK vægtkontrol i atrieflimren undersøgelse, et multicenter, dobbeltblindt, randomiseret, parallel gruppe, placebokontrolleret forsøg
Quantify the effect of an innovative weight loss management on rhythm control.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Rationale: Weight reduction promotes reversed atrial remodeling in obese AF patients.
Objective: Quantify the effect of an innovative weight loss management on rhythm control.
Study design: Multi-center, double-blind, randomized, parallel group, placebo-controlled trial of semaglutide 2.4 mg versus placebo.
Study population: Adults with obesity and new onset persistent AF scheduled for electrical cardioversion.
Intervention: semaglutide 2.4 mg subcutaneous (s.c.) once weekly (index) compared to placebo (control), at the background of standard obesity treatment (combined lifestyle intervention) and cardiology follow-up management in both arms.
Main study parameters/endpoints: The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome. The 7 mutually exclusive outcomes hierarchically ranked from worst to best are:
-
Arrhythmic death while using anti-arrhythmic drugs (Vaughn-Williams class I or III)*
-
AF despite pulmonary vein isolation
-
AF despite current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
-
AF without a pulmonary vein isolation and without the current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
-
Sinus rhythm on the 12-lead ECG with the use of a pulmonary vein isolation
-
Sinus rhythm on the 12-lead ECG with current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
-
Sinus rhythm on the 12-lead ECG without the current use of anti-arrhythmic drugs (Vaughn-Williams class I or III) and without a pulmonary vein isolation
- When LTFU or death other than anti-arrhythmic death, last known rhythm will be used.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
's-Hertogenbosch, Holland
- Jeroen Bosch Ziekenhuis
-
Alkmaar, Holland
- Noordwest Ziekenhuisgroep
-
Amsterdam, Holland
- Amsterdam UMC
-
Breda, Holland
- Amphia Ziekenhuis
-
Deventer, Holland
- Deventer Ziekenhuis
-
Doetinchem, Holland
- Slingeland Ziekenhuis
-
Eindhoven, Holland
- Máxima MC
-
Emmen, Holland
- Treant Zorggroep
-
Goes, Holland
- Admiraal de Ruyter Ziekenhuis
-
Groningen, Holland
- Martini Ziekenhuis
-
Groningen, Holland
- Universitair Medisch Centrum Groningen
-
Haarlem, Holland
- Spaarne Gasthuis
-
Heerlen, Holland
- Zuyderland Medisch Centrum
-
Leeuwarden, Holland
- Frisius MC
-
Maastricht, Holland
- Maastricht UMC+
-
Roosendaal, Holland
- Bravis ziekenhuis
-
The Hague, Holland
- HagaZiekenhuis
-
The Hague, Holland
- Haaglanden Medisch Centrum
-
Utrecht, Holland
- Diakonessenhuis
-
-
Gelderland
-
Arnhem, Gelderland, Holland
- Rijnstate Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Symptomatic, first detected (at maximum 6 months prior to enrollment) persistent AF -
-
Age ≥ 18
-
Obesity, as defined as:
- BMI ≥ 30 kg/m2, or
- BMI ≥27 kg/m2 with the presence of at least one weight related comorbidity (treated or untreated, e.g. hypertension, dyslipidaemia, obstructive sleep apnea, cardiovascular disease)
-
Scheduled ECV
-
Written informed consent
Exclusion Criteria:
- Permanent AF
- Secondary AF, i.e. due to thyrotoxicosis, infection (e.g. pneumonia) or post-(cardiothoracic) surgery
- Current or previous treatment with amiodaron
- HbA1c ≥ 48 mmol/mol, <3 months prior to randomization
- History of diabetes mellitus type 1 or 2
- Prior bariatric surgery
- Use of other anti-obesity medication, <3 months prior to enrollment
- Contra-indication for, or prior use of a GLP1-receptor agonist
- History of chronic pancreatitis or acute pancreatitis <6 months
- Acute coronary syndrome <6 months
- Severe (grade III) valvular disease
- eGFR <30 mL/min/1.73m2
- Heart failure NYHA class III-IV
- Participation in another investigational drug or device study in the past 30 days (registry enrollment is allowed)
- Any condition or therapy, which would make the participant unsuitable for the study (e.g. vulnerable, non-compliance) or life-expectancy <12 months, as judged by the treating physician.
- Female who is pregnant, breastfeeding, intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Intervention
Semaglutide injections + combined lifestyle intervention |
Intervention arm receives semaglutide in addition to combined lifestyle intervention |
|
Placebo komparator: Placebo
Placebo Semaglutide injections + combined lifestyle intervention |
Control arm receives placebo in addition to combined lifestyle intervention |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome
Tidsramme: At 1 year follow-up
|
The 7 mutually exclusive outcomes hierarchically ranked from worst to best are:
|
At 1 year follow-up
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Antal indlæggelser på grund af tilbagefald af AF.
Tidsramme: uge 0-52
|
uge 0-52
|
|
|
Antal ikke-planlagte hospitalsbesøg på grund af uønskede hændelser af AAD.
Tidsramme: uge 0-52
|
uge 0-52
|
|
|
Antal planlagte elektriske elkonverteringer.
Tidsramme: uge 0-52
|
uge 0-52
|
|
|
Antal ikke-planlagte elektriske elkonverteringer.
Tidsramme: uge 0-52
|
uge 0-52
|
|
|
Antal intravenøse kemiske kardioversioner (ved brug af Vaughan-Williams klasse I-lægemidler).
Tidsramme: uge 0-52
|
uge 0-52
|
|
|
Samlet antal uplanlagte cardioverioner.
Tidsramme: uge 0-52
|
uge 0-52
|
|
|
Ændring i taljeomkreds, målt i cm
Tidsramme: uge 0 og 52
|
uge 0 og 52
|
|
|
Ændring i vægt, målt i % og kg
Tidsramme: uge 0 og 52
|
uge 0 og 52
|
|
|
Ændring i BMI, målt i kg/m2
Tidsramme: uge 0 og 52
|
uge 0 og 52
|
|
|
Change in AF related symptoms measured by the modified EHRA classification between the index visit and at 12 months after the index visit.
Tidsramme: week 0 and 52
|
EHRA: European Heart Rythm Association 1= no symptoms 2a= mild symptoms; Normal dialy activity not affected, symptoms not troublesome to patient 2b= moderate symptoms; Normal daily activity not affected but patient troubled by symptoms 3= severe symptoms; Normal daily activity affected 4= disabling symptoms; Normal daily activity discontinued |
week 0 and 52
|
|
Change in quality of life measured by the EQ-5D-5L between the index visit and at 12 months after the index visit.
Tidsramme: week 0 and 52
|
Descriptive system for health-related quality of life states in adults, consisting of five dimensions (Mobility, Self-care, Usual activities, Pain & discomfort, Anxiety & depression), each of which has five severity levels that are described by statements appropriate to that dimension. LEVEL 1: indicating no problem LEVEL 2: indicating slight problems LEVEL 3: indicating moderate problems LEVEL 4: indicating severe problems LEVEL 5: indicating unable to/extreme problems |
week 0 and 52
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Ron Pisters, dr., Rijnstate Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- U1111-1275-9989
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .